CPT code 0321U designates a proprietary laboratory molecular assay — the Bridge Urinary Tract Infection Detection and Resistance Test from Bridge Diagnostics — that identifies up to 20 specific bacterial or fungal organisms in urine and screens for 16 antibiotic resistance genes. The code matters nationally as molecular diagnostics for urinary tract infections (UTIs) can change diagnostic workflows, influence antibiotic stewardship, and affect reimbursement and coverage policies as labs adopt proprietary panels.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose of the test, typical service setting, and which payers are addressed. The publication summarizes common billing modifiers and situates the code within laboratory service lines. It also outlines what to expect in policy and coverage reviews for PLA codes, how this test fits into antibiotic-resistance detection efforts, and practical considerations for documentation and claims submission.

This national-oriented summary provides clinicians, laboratory administrators, and billing professionals with the clinical context and payer focus needed to assess adoption implications and prepare for payer-specific policy inquiries and claims processing.